TXMD
TherapeuticsMD Inc
$
1.061
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.100
Open
1.100
VWAP
1.07
Vol
19.00K
Mkt Cap
12.28M
Low
1.055
Amount
20.31K
EV/EBITDA(TTM)
--
Total Shares
11.53M
EV
6.99M
EV/OCF(TTM)
3.33
P/S(TTM)
6.96
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Show More
Valuation Metrics
The current forward P/E ratio for TherapeuticsMD Inc (TXMD.O) is 6.91, compared to its 5-year average forward P/E of -0.96. For a more detailed relative valuation and DCF analysis to assess TherapeuticsMD Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.96
Current PE
6.91
Overvalued PE
8.78
Undervalued PE
-10.70
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.74
Current EV/EBITDA
0.10
Overvalued EV/EBITDA
1.81
Undervalued EV/EBITDA
-5.30
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.16
Current PS
1.38
Overvalued PS
9.08
Undervalued PS
-0.76
Financials
Annual
Quarterly
FY2025Q1
YoY :
+25.56%
393.00K
Total Revenue
FY2025Q1
YoY :
-31.44%
-783.00K
Operating Profit
FY2025Q1
YoY :
-21.38%
-636.00K
Net Income after Tax
FY2025Q1
YoY :
-0.00%
-0.06
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-37.39%
-161.83
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
4
2.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
4
2.8K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TXMD News & Events
Events Timeline
2025-05-13 (ET)
2025-05-13
16:13:37
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
Sign Up For More Events
Sign Up For More Events
News
9.5
03-26BenzingaWhy GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
4.5
2024-08-26BenzingaTherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
8.4
2024-08-12Business InsiderTXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
Sign Up For More News
People Also Watch
SSKN
Strata Skin Sciences Inc
1.780
USD
-6.81%
LEDS
SemiLEDs Corp
1.620
USD
+6.23%
HCWC
Healthy Choice Wellness Corp
0.410
USD
-2.38%
JBDI
JBDI Holdings Ltd
1.000
USD
-1.96%
PETZ
TDH Holdings Inc
1.025
USD
+3.53%
WBUY
Webuy Global Ltd
3.150
USD
+0.96%
NITO
N2OFF Inc
0.245
USD
+2.52%
HTOO
Fusion Fuel Green PLC
4.250
USD
-5.97%
YYAI
Connexa Sports Technologies Inc
4.750
USD
+4.86%
CISO
CISO Global Inc
0.942
USD
+0.11%
FAQ
What is TherapeuticsMD Inc (TXMD) stock price today?
The current price of TXMD is 1.0613 USD — it has decreased -3.55 % in the last trading day.
What is TherapeuticsMD Inc (TXMD)'s business?
What is the price predicton of TXMD Stock?
What is TherapeuticsMD Inc (TXMD)'s revenue for the last quarter?
What is TherapeuticsMD Inc (TXMD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for TherapeuticsMD Inc (TXMD)'s fundamentals?
How many employees does TherapeuticsMD Inc (TXMD). have?